![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 2022
February 24, 2022
Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022
ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022
On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
February 24, 2022
Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
February 24, 2022
This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
February 24, 2022
The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
February 24, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more